First-in-Human cancer pill targets specific gene fault
NCT ID NCT02122913
Summary
This first-in-human study tested the safety and effects of an oral drug called larotrectinib in adults with advanced solid tumors that have a specific genetic change (NTRK fusion). The trial involved 75 patients for whom other effective therapies did not exist. Researchers aimed to find a safe dose and see how the body processes the drug, which is designed to block the faulty gene driving the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS HARBORING NTRK FUSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania - Radiology
Philadelphia, Pennsylvania, 19104, United States
-
Mass General Cancer Center
Boston, Massachusetts, 02114, United States
-
OHSU Hospital - Neurology
Portland, Oregon, 97239, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center - Texas Medical Center
Houston, Texas, 77030, United States
-
UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
UH Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
UPMC Mercy - Oncology
Pittsburgh, Pennsylvania, 15219, United States
Conditions
Explore the condition pages connected to this study.